WED-316-YI Treatment response to bulevirtide leads to improvement of portal hypertension in patients with chronic hepatitis D virus infection: results from the prospective IMPHROVE-D study
Lisa Sandmann(Medizinische Hochschule Hannover), Benjamin Maasoumy(Medizinische Hochschule Hannover), Michael Schwarz(Medical University of Vienna), Birgit Bremer(Medizinische Hochschule Hannover), Paul Thöne(Medical University of Vienna), Lukas Hartl(Medical University of Vienna), Christine S. Falk(Medizinische Hochschule Hannover), Tammo Lambert Tergast(Medizinische Hochschule Hannover), Heiner Wedemeyer(Medizinische Hochschule Hannover), Thomas Reiberger(ERN GUARD-Heart), Benedikt Hofer(Austrian Academy of Sciences), Albert Friedrich Stättermayer(Medical University of Vienna), Mathias Jachs(Medical University of Vienna), Katja Deterding(Medizinische Hochschule Hannover), Michael Trauner(Medical University of Vienna), Lorenz Balcar(Medical University of Vienna), Julius Egge, Mattias Mandorfer(Medical University of Vienna), Martin Kabelitz(Medizinische Hochschule Hannover), Markus Cornberg(Medizinische Hochschule Hannover)
Cited by 0
Related Papers
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817